NASDAQ:ASMB Assembly Biosciences Q4 2024 Earnings Report $23.67 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$23.72 +0.04 (+0.19%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Assembly Biosciences EPS ResultsActual EPS-$1.57Consensus EPS -$1.75Beat/MissBeat by +$0.18One Year Ago EPSN/AAssembly Biosciences Revenue ResultsActual Revenue$7.36 millionExpected Revenue$7.05 millionBeat/MissBeat by +$310.00 thousandYoY Revenue GrowthN/AAssembly Biosciences Announcement DetailsQuarterQ4 2024Date3/20/2025TimeBefore Market OpensConference Call DateThursday, March 20, 2025Conference Call Time4:00PM ETUpcoming EarningsAssembly Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Assembly Biosciences Earnings HeadlinesAssembly Biosciences (ASMB) Receives a Buy from Mizuho SecuritiesSeptember 12, 2026 | theglobeandmail.comAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | markets.businessinsider.comArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.25 g/t. After roughly 21,000 metres of drilling, the company is closing in on its first-ever mineral resource estimate, expected in Q3 or Q4 2026. That estimate could offer the market its first real look at the scale of this emerging gold system.September 28 at 1:00 AM | Wall Street Logic (Ad)Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comAssembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With GileadSeptember 8, 2026 | finance.yahoo.comAssembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor ProgramSeptember 8, 2026 | globenewswire.comSee More Assembly Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email. Email Address About Assembly BiosciencesAssembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control. The company’s pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle. Assembly is also developing antiviral candidates for herpes simplex virus (HSV), including ABI-5366, a long-acting helicase-primase inhibitor intended to prevent viral replication. These programs remain investigational and are subject to clinical and regulatory evaluation. Assembly Biosciences has historically advanced its programs through a combination of internal research and strategic collaboration. The company entered into a collaboration with Gilead Sciences covering certain HBV research and development activities. Assembly is led by William M. Collier, who serves as president and chief executive officer.View Assembly Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
